Cardiorenal care coordination: holistic patient care opportunities in the primary care setting for patients with chronic kidney disease and atherosclerotic cardiovascular disease

被引:1
作者
Miller, Eden [1 ,5 ]
Raj, Dominic [2 ]
Cavender, Matthew A. [3 ]
Mehanna, Sherif [4 ]
Namvar, Tarlan [4 ]
Ochsner, Reese [4 ]
机构
[1] Diabet & Obes Care LLC, Bend, OR USA
[2] George Washington Univ, Div Kidney Dis & Hypertens, Washington, DC USA
[3] Univ N Carolina, Carrboro, NC USA
[4] Novo Nordisk Inc, Plainsboro, NJ USA
[5] Diabet & Obes Care LLC, 185 SW Shevlin Hixon Dr,Suite 111, Bend, OR 97702 USA
关键词
renal insufficiency; cardiovascular disease; physicians; chronic kidney disease; cross-sectional studies; atherosclerosis; MANAGEMENT; DIAGNOSIS; ADULTS; CKD;
D O I
10.1080/00325481.2023.2256209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) are closely linked conditions, and the presence of each condition promotes incidence and progression of the other. In this study, we sought to better understand the medical journey of patients with CKD and ASCVD and to uncover patients' and healthcare providers' (HCPs) perceptions and attitudes toward CKD and ASCVD diagnosis, treatment, and care coordination.Methods: Cross-sectional, US-population-based online surveys were conducted between May 18, 2021, and June 17, 2021, among 239 HCPs (70 of whom were primary care physicians, or PCPs) and 195 patients with CKD and ASCVD.Results: PCPs reported personally diagnosing CKD in 78% and ASVD in 64% of their patients, respectively. PCPs reported they are more likely to serve as the overall coordinator of their patient's care (89%), while slightly more than half of PCPs self-identified as a patient's coordinator of care specifically for CKD (54%) or ASCVD (59%). In contrast, patients viewed their PCP as their coordinator of care for CKD (25%) or ASCVD (9%). PCPs who personally treated patients with CKD and ASCVD most often recalled primarily prescribing or recommending pharmacologic treatments for CKD and ASCVD; however, patients reported that lifestyle modification was the most common treatment modality they had ever used to manage CKD and ASCVD.Conclusion: CKD and ASCVD are interrelated cardiometabolic conditions with underlying risk factors that can be managed in a primary care setting. However, few patients in our study considered their PCP to be the coordinator of their care for CKD or ASCVD. PCPs can and should take a more active role in educating patients and coordinating care for those with CKD and ASCVD.
引用
收藏
页码:708 / 716
页数:9
相关论文
共 31 条
  • [1] Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study
    Amdur, Richard L.
    Feldman, Harold I.
    Dominic, Elizabeth A.
    Anderson, Amanda H.
    Beddhu, Srinivasan
    Rahman, Mahboob
    Wolf, Myles
    Reilly, Muredach
    Ojo, Akinlolu
    Townsend, Raymond R.
    Go, Alan S.
    He, Jiang
    Xie, Dawei
    Thompson, Sally
    Budoff, Matthew
    Kasner, Scott
    Kimmel, Paul L.
    Kusek, John W.
    Raj, Dominic S.
    Fink, Jeffrey
    Appel, Lawrence J.
    Lash, James P.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 344 - 353
  • [2] Inflammation and Progression of CKD: The CRIC Study
    Amdur, Richard L.
    Feldman, Harold I.
    Gupta, Jayanta
    Yang, Wei
    Kanetsky, Peter
    Shlipak, Michael
    Rahman, Mahboob
    Lash, James P.
    Townsend, Raymond R.
    Ojo, Akinlolu
    Roy-Chaudhury, Akshay
    Go, Alan S.
    Joffe, Marshall
    He, Jiang
    Balakrishnan, Vaidyanathapuram S.
    Kimmel, Paul L.
    Kusek, John W.
    Raj, Dominic S.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (09): : 1546 - 1556
  • [3] American Diabetes Association, 2022, GETT GOAL OV THER IN
  • [4] [Anonymous], 2013, KIDNEY INT SUPPL, V3, P1, DOI [10.1038/kisup.2012.76, DOI 10.1038/KISUP.2012.76, DOI 10.1038/KISUP.2012.73]
  • [5] Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
    Bajaj, Archna
    Xie, Dawei
    Cedillo-Couvert, Esteban
    Charleston, Jeanne
    Chen, Jing
    Deo, Rajat
    Feldman, Harold, I
    Go, Alan S.
    He, Jiang
    Horwitz, Edward
    Kallem, Radhakrishna
    Rahman, Mahboob
    Weir, Matthew R.
    Anderson, Amanda H.
    Rader, Daniel J.
    Appel, Lawrence J.
    Kusek, John W.
    Lash, James P.
    Rao, Panduranga S.
    Townsend, Raymond R.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (06) : 827 - 836
  • [6] Bakris George, 2022, J Fam Pract, V71, pS88, DOI 10.12788/jfp.0389
  • [7] Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial
    Branch, Mary
    German, Charles
    Bertoni, Alain
    Yeboah, Joseph
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (07) : 468 - 472
  • [8] Centers for Disease Control and Prevention, 2021, ABOUT US
  • [9] Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities
    Chaudhry, Rafia, I
    Mathew, Roy O.
    Sidhu, Mandeep S.
    Sidhu-Adler, Preety
    Lyubarova, Radmila
    Rangaswami, Janani
    Salman, Loay
    Asif, Arif
    Fleg, Jerome L.
    McCullough, Peter A.
    Maddux, Frank
    Bangalore, Sripal
    [J]. CARDIORENAL MEDICINE, 2018, 8 (04) : 285 - 295
  • [10] Chronic Kidney Disease Diagnosis and Management: A Review
    Chen, Teresa K.
    Knicely, Daphne H.
    Grams, Morgan E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (13): : 1294 - 1304